Wednesday, April 17, 2024 3:05:10 PM
"The dividend distribution of rights will be payable to stockholders of record as of the close of business on April 29, 2024."
A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.
A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.
Guess we'll have to wait on the promised 8K.
Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends.
A shareholder may also receive distributions such as additional stock or stock rights in the distributing corporation; such distributions may or may not qualify as dividends. You should receive a Form 1099-DIV, Dividends and Distributions from each payer for distributions of at least $10.
Guess we'll have to wait on the promised 8K.
Additional details of the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC"). The filing will be available on the SEC's website at www.sec.gov.
saving nickels saving dimes
working till the sun don't shine
looking forward to happier times
1963, Roy Orbison - On Blue Bayou
Recent VNDA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/20/2026 08:49:38 PM
- Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences • PR Newswire (US) • 05/07/2026 10:44:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:01:32 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:06:17 PM
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results • PR Newswire (US) • 05/06/2026 08:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/06/2026 04:15:14 AM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/04/2026 12:00:00 PM
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years • PR Newswire (US) • 05/01/2026 08:35:00 PM
- Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026 • PR Newswire (US) • 04/29/2026 08:30:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/29/2026 08:08:37 PM
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence • PR Newswire (US) • 04/28/2026 11:12:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/24/2026 08:35:12 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:50:50 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:48:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2026 09:23:06 PM
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors • PR Newswire (US) • 04/22/2026 09:13:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:38:37 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:37:04 PM
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines • PR Newswire (US) • 04/09/2026 03:02:00 PM
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists • PR Newswire (US) • 04/08/2026 08:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:32 PM
- Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods • PR Newswire (US) • 03/19/2026 08:34:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:54:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 11:51:51 PM
